search
Back to results

TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS (TTV-CART)

Primary Purpose

Hematologic Cancer

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
blood collection
Sponsored by
Institut Paoli-Calmettes
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Hematologic Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult patients (>=18 years).
  2. Patient going to be treated by CAR-T Cell therapy
  3. Able to comply with the protocol.
  4. Written informed consent.
  5. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen

Exclusion Criteria:

  1. Pregnancy/breast feeding.
  2. Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    STUDY ARM

    Arm Description

    blood samples collection

    Outcomes

    Primary Outcome Measures

    Plasma viral load and TTV replication kinetics
    comparaition between before during and after CART

    Secondary Outcome Measures

    Plasma viral load and CMV replication kinetics
    comparaition between before during and after CART
    infections
    Reported infections during the study
    Cytokines
    Cytokines comparison between samples

    Full Information

    First Posted
    March 24, 2021
    Last Updated
    March 26, 2021
    Sponsor
    Institut Paoli-Calmettes
    Collaborators
    Hospital Clínico Universitario de Valencia
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04822974
    Brief Title
    TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
    Acronym
    TTV-CART
    Official Title
    TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE RISK OF CYTOKINE RELEASE SYNDROME AND DIFFERENTIAL DIAGNOSIS WITH INFECTION
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2021
    Overall Recruitment Status
    Unknown status
    Study Start Date
    May 1, 2021 (Anticipated)
    Primary Completion Date
    May 1, 2022 (Anticipated)
    Study Completion Date
    September 1, 2022 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Institut Paoli-Calmettes
    Collaborators
    Hospital Clínico Universitario de Valencia

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Torque Teno Virus (TTV) prevalence in the general population is very high (>90%) and has not been consistently confirmed to cause any disease. Kidney transplant studies seem to indicate that an elevated viremia could predict the risk of de-veloping an infectious process in the following weeks. An study of the influence of TTV as a predictive marker of infection in kidney transplant recipi-ents showed higher TTV levels, even 3 months before the infectious process, allowing the authors to postulate that the quantification of TTV could help to modulate the treatment of patients at risk. Publications of subsequent studies seem to confirm these data.In the field of hematopoietic stem cell transplantation (HSCT) few studies have analyzed the replication kinetics of TTV. There seems to be a drop in TTV plasma load after conditioning treatment, with a progressive increase in the first months post-transplant, in parallel with the number of lymphocytes. In early stages of HSCT, a relation-ship between TTV replication kinetics and the probability of developing an infection by CMV has also been described. Likewise, the possible relationship of TTV with other complications of HSCT, such as Epstein-Barr virus infection (EBV) or graft-versus-host disease (GvHD), have been reported. However, not every study conducted to date show this line of results.
    Detailed Description
    Torque Teno Virus (TTV) is the prototype of the Anelloviridae family-single chain and circular viruses. These viruses form about 70% of the human virome. TTV prevalence in the general population is very high (>90%) and has not been consistently confirmed to cause any disease. Kidney transplant studies seem to indicate that an elevated viremia could predict the risk of de-veloping an infectious process (bacterial, viral or fungal) in the following weeks. A group of research analyzed the influence of TTV as a predictive marker of infection in 169 kidney transplant recipi-ents. Patients with infection showed higher TTV levels, even 3 months before the infectious process, allowing its authors to postulate that the quantification of TTV could help to modulate the treatment of patients at risk (reducing immunosuppression, introducing or prolonging antimi-crobial prophylaxis). Publications of subsequent studies with greater number of patients seem to confirm these data. Likewise, in the specific case of CMV infection, the quantification of TTV in the early stages of kidney or liver transplantation also allows identification of patients at risk of developing a CMV infection. In the field of hematopoietic stem cell transplantation (HSCT) few studies have analyzed the replication kinetics of TTV. There seems to be a drop in TTV plasma load after conditioning treatment, with a progressive increase in the first months post-transplant, in parallel with the number of lymphocytes. In early stages of HSCT, a relation-ship between TTV replication kinetics and the probability of developing an infection by CMV has also been described. Likewise, the possible relationship of TTV with other complications of HSCT, such as Epstein-Barr virus infection (EBV) or graft-versus-host disease (GvHD), have been reported. However, not every study conducted to date show this line of results. An other research analyzed 2054 blood samples from 123 patients undergoing HSCT, finding no significant differences between TTV and post-transplant complications, such as viral reactivations (CMV, EBV or adenovirus), acute GvHD, relapse or mortality

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hematologic Cancer

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    STUDY ARM
    Arm Type
    Experimental
    Arm Description
    blood samples collection
    Intervention Type
    Other
    Intervention Name(s)
    blood collection
    Intervention Description
    longitudinally collection of blood samples for each patient included.
    Primary Outcome Measure Information:
    Title
    Plasma viral load and TTV replication kinetics
    Description
    comparaition between before during and after CART
    Time Frame
    d0, d1, d3, d5, d7, d10, d14, d21, d28, d60 and d90 after CAR-T Cell treatment
    Secondary Outcome Measure Information:
    Title
    Plasma viral load and CMV replication kinetics
    Description
    comparaition between before during and after CART
    Time Frame
    d0, d14, d28, d60 and d90 after CAR-T Cell treatment
    Title
    infections
    Description
    Reported infections during the study
    Time Frame
    100 days
    Title
    Cytokines
    Description
    Cytokines comparison between samples
    Time Frame
    d0, d3, d7, d10 and d14 after CAR-T Cell treatment

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult patients (>=18 years). Patient going to be treated by CAR-T Cell therapy Able to comply with the protocol. Written informed consent. Patient affiliated to the national "Social Security" regimen or beneficiary of this regimen Exclusion Criteria: Pregnancy/breast feeding. Patient considered socially or psychologically unable to comply with the treatment and the required medical follow-up.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    DOMINIQUE GENRE, DR
    Phone
    0491223778
    Email
    drci.up@ipc.unicancer.fr

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS

    We'll reach out to this number within 24 hrs